Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Gene therapy using hematopoietic stem cells.

¹Department of Pediatrics, University of Southern California School of Medicine, Children's Hospital, Los Angeles 90027, USA. dkohn@chla.usc.edu

Current Opinion in Molecular Therapeutics

|November 21, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The treatment of adenosine deaminase deficiency.

Immunology today·2014

Same author

Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.

Gene therapy·2010

Same author

Lentiviral vectors with amplified beta cell-specific gene expression.

Gene therapy·2009

Same author

Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors.

Gene therapy·2008

Same author

Gene therapy for childhood immunological diseases.

Bone marrow transplantation·2007

Same author

The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors.

Gene therapy·2007

Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011

Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010

Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010

Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010

Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010

Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010

See all related articles

Gene therapy for hematopoietic stem cells (HSCs) shows promise with improved gene transfer methods. Advances in viral vectors are enabling stable HSC transduction, moving from animal models to clinical trials.

Area of Science:

Biomedical research
Gene therapy
Hematology

Background:

Hematopoietic stem cell (HSC) gene therapy has long been investigated but faced challenges.
Early attempts at gene transfer and expression in HSCs yielded limited success.

Purpose of the Study:

To highlight recent advancements in gene therapy for hematopoietic stem cells.
To discuss the potential of novel gene transfer vectors for stable HSC transduction.

Main Methods:

Review of recent developments in gene transfer and expression technologies for HSCs.
Evaluation of retroviral, adeno-associated, and lentiviral vectors for HSC transduction.
Analysis of data from animal transplant models.

Main Results:

Related Experiment Videos

Significant progress has been made in enhancing gene transfer and expression efficiency in HSCs.
Adeno-associated and lentiviral vectors show promise for stable HSC transduction.
Successful application of these advances in animal models.

Conclusions:

Current advancements in gene therapy vectors are overcoming previous limitations in HSC treatment.
These improved methods are transitioning from preclinical animal studies to human clinical trials.
The potential for effective HSC gene therapy is increasing due to vector development.